The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...
The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are ...
Indications now include pediatric plaque psoriasis and active PsA starting at age 6, positioning risankizumab as the first US-approved IL-23(p19) inhibitor for <40 kg pediatric patients. Weight-tiered ...
Researchers report encouraging early results from a first-in-human clinical trial led by Children's National Hospital using a ...
A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID.
The interleukin 23 inhibitor was approved for treating moderate-to-severe plaque psoriasis in adults in 2019 and for active ...
Many oral drugs show a high variability in pharmacokinetic exposure, and, for drugs with exposure related to efficacy, therapeutic drug monitoring can help optimize exposure in individual patients.
Merz Therapeutics announced the FDA approved a label update to expand incobotulinumtoxinA’s pediatric upper limb spasticity ...
The FDA has approved an expanded indication for Zoryve (roflumilast) cream 0.3% to include plaque psoriasis in pediatric patients aged 2 years and older.
Mission Prep Healthcare has released a new guide on trazodone as an off-label insomnia treatment for teenagers, covering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results